PurMinds NeuroPharma
- Founded: 2020
- Location: Toronto, ON
- Employee range: 11 - 50
- Clinical stage: Clin0
- Therapy area: TBI, Parkinson's, ALS
- Drug types: NEU, X_X
- Lead product: PUR001A
- Product link: https://www.purminds.com/the-purprecision-platform
- Funding: not disclosed
purminds.com linkedin.com job board
Short description:
Neuro Drug Discovery
Drug notes:
PUR001B Clin0 brain injury, neurodegenerative diseases; PUR002 Clin0 stroke, Parkinson's
Long description:
PurMinds NeuroPharma is developing disease-modifying therapeutics for neurological conditions. Psychedelic compounds have a bad reputation, however they offer much potential for treating neurological conditions due to their neuroplasticity effects. PurMinds owns and operates a portfolio of assets and licenses enabling them to produce, sell and export psychedelic compounds including psilocybin, MDMA, LSD and DMT. Using their PurPrecision practice, PurMinds is using a data-driven approach to validate therapeutics and stratify patient recruitment in clinical trials. PurMinds lead candidate, PUR101, is a botanical psilocybin formulation that is going through preclinical stages to treat patients with depression in neurological disorders.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com